Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Cardiovascular Disease Risk in End-Stage Renal Disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 04 2020
06 04 2020
Historique:
received:
02
09
2019
accepted:
17
03
2020
entrez:
7
4
2020
pubmed:
7
4
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Plasma leucine-Rich α-2-glycoprotein 1 (LRG1) is an innovative biomarker for inflammation and angiogenesis. Many adverse pathophysiological changes including inflammation, atherosclerosis, and premature mortality is associated with End-stage renal disease (ESRD). However, whether levels of plasma LRG1 correlate with the co-morbidities of ESRD patients is unknown. Plasma LRG1 and high-sensitivity C-reactive protein (hsCRP) were analyzed by ELISA in 169 hemodialysis patients from the Immunity in ESRD (iESRD) study. Patient demographics and comorbidities at the time of enrollment were recorded. Peripheral blood monocyte and T cell subsets were assessed by multicolor flow cytometry. In the univariate analysis, a higher level of LRG1 was associated with the presence of cardiovascular disease (CVD) and peripheral arterial occlusive disease (PAOD). In multivariate logistic regression models, higher LRG1 tertile was significantly associated with PAOD (odds ratio = 3.49) and CVD (odds ratio = 1.65), but not with coronary artery disease, history of myocardial infarction, or stroke after adjusting for gender, diabetes, hemoglobin, albumin, calcium-phosphate product, and level of hsCRP. In addition, the level of LRG1 had a positive correlation with IL-6, hsCRP, and also more advanced T cell differentiation. The association suggests that LRG1 participates in the progression of atherosclerosis by inducing inflammation. Therefore, the role of LRG1 in coexisting inflammatory response should be further investigated in the pathogenesis of cardiovascular morbidity and mortality in patients with ESRD.
Identifiants
pubmed: 32249825
doi: 10.1038/s41598-020-62989-7
pii: 10.1038/s41598-020-62989-7
pmc: PMC7136266
doi:
Substances chimiques
Biomarkers
0
Glycoproteins
0
LRG1 protein, human
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5988Références
Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 9(12 Suppl), S16–23 (1998).
pubmed: 11443763
Rayner, H. C. et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transpl. 19(1), 108–20 (2004).
doi: 10.1093/ndt/gfg483
Longenecker, J. C. et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J. Am. Soc. Nephrol. 13(7), 1918–27 (2002).
doi: 10.1097/01.ASN.0000019641.41496.1E
Weiner, D. E. et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 73(12), 1406–12 (2008).
doi: 10.1038/ki.2008.75
Zewinger, S. et al. Innate immunity in CKD-associated vascular diseases. Nephrol. Dial. Transpl. 31(11), 1813–1821 (2016).
doi: 10.1093/ndt/gfv358
Ng, A. C. et al. Human leucine-rich repeat proteins: a genome-wide bioinformatic categorization and functional analysis in innate immunity. Proc. Natl Acad. Sci. U S A 108(Suppl 1), 4631–8 (2011).
doi: 10.1073/pnas.1000093107
Haupt, H. & Baudner, S. [Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum (author’s transl)]. Hoppe Seylers Z. Physiol. Chem. 358(6), 639–46 (1977).
doi: 10.1515/bchm2.1977.358.1.639
Weivoda, S. et al. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J. Immunol. Methods 336(1), 22–9 (2008).
doi: 10.1016/j.jim.2008.03.004
Bini, L. et al. Two-dimensional electrophoretic patterns of acute-phase human serum proteins in the course of bacterial and viral diseases. Electrophoresis 17(3), 612–6 (1996).
doi: 10.1002/elps.1150170333
Serada, S. et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm. Bowel Dis. 18(11), 2169–79 (2012).
doi: 10.1002/ibd.22936
Ahn, S.S. et al. Serum leucine-rich alpha2-glycoprotein is elevated in patients with systemic lupus erythematosus and correlates with disease activity. Clin Chim Acta (2018).
Honda, H. et al. Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma. PLoS One 11(9), e0162672 (2016).
doi: 10.1371/journal.pone.0162672
Pek, S. L. et al. Elevation of a novel angiogenic factor, leucine-rich-alpha2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 100(4), 1586–93. (2015).
doi: 10.1210/jc.2014-3855
Lee, H. et al. Leucine rich α-2 glycoprotein is a potential urinary biomarker for renal tubular injury. Biochem. Biophys. Res. Commun. 498(4), 1045–1051 (2018).
doi: 10.1016/j.bbrc.2018.03.111
Glorieux, G. et al. New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol. Dial. Transpl. 30(11), 1842–52 (2015).
doi: 10.1093/ndt/gfv254
Chiu, Y. L. et al. A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: the iESRD study. Immun. Ageing 15, 27 (2018).
doi: 10.1186/s12979-018-0131-x
Zawada, A. M. et al. Monocyte heterogeneity in human cardiovascular disease. Immunobiology 217(12), 1273–84 (2012).
doi: 10.1016/j.imbio.2012.07.001
Rogacev, K. S. et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur. Heart J. 32(1), 84–92 (2010).
doi: 10.1093/eurheartj/ehq371
Andersson, J., Libby, P. & Hansson, G. K. Adaptive immunity and atherosclerosis. Clin. Immunol. 134(1), 33–46 (2009).
doi: 10.1016/j.clim.2009.07.002
Ammirati, E. et al. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. J. Am. Heart Assoc. 1(1), 27–41 (2012).
doi: 10.1161/xJAHA.111.000125
Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1), 23–33 (1999).
doi: 10.1016/S0092-8674(00)80059-8
Yu, H. T., et al., Arterial Stiffness Is Associated With Cytomegalovirus-Specific Senescent CD8(+) T Cells. J Am Heart Assoc, 6(9) (2017).
Pek, S. L. T., et al., Association of circulating proinflammatory marker, leucine-rich-alpha2-glycoprotein (LRG1), following metabolic/bariatric surgery. Diabetes Metab Res Rev: p. e3029, (2018).
Yang, T. O., Chuang, Y. F. & Chiu, Y. L. T-cell aging in end-stage renal disease: an evolving story with CMV. Med. Microbiol. Immunol. 208(3-4), 281–287 (2019).
doi: 10.1007/s00430-019-00596-8
Yang, F. J. et al. Anti-cytomegalovirus IgG antibody titer is positively associated with advanced T cell differentiation and coronary artery disease in end-stage renal disease. Immun. Ageing 15, 15 (2018).
doi: 10.1186/s12979-018-0120-0
Chiu, Y. L. et al. Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol. Dial. Transpl. 24(1), 247–51 (2009).
doi: 10.1093/ndt/gfn439
Bernelot Moens, S. J. et al. Arterial and Cellular Inflammation in Patients with CKD. J. Am. Soc. Nephrol. 28(4), 1278–1285 (2017).
doi: 10.1681/ASN.2016030317
Stenvinkel, P., Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant, 17 Suppl 8: p. 33–8; discussion 40 (2002).
Wang, X. et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499(7458), 306–11 (2013).
doi: 10.1038/nature12345
Zhang, J. et al. LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1alpha activation. J. Exp. Clin. Cancer Res. 35, 29 (2016).
doi: 10.1186/s13046-016-0306-2
Liu, J. J. et al. Plasma Leucine-Rich alpha-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus. J. Clin. Endocrinol. Metab. 102(10), 3683–3691 (2017).
doi: 10.1210/jc.2017-00930
Fu, J. et al. Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice. Kidney Int. 94(2), 326–345 (2018).
doi: 10.1016/j.kint.2018.02.028
Watson, C. J. et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ. Heart Fail. 4(2), 188–97 (2011).
doi: 10.1161/CIRCHEARTFAILURE.110.952200
Kumagai, S. et al. Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction. Cardiovasc. Res. 109(2), 272–82 (2016).
doi: 10.1093/cvr/cvv273
O’Hare, A. & Johansen, K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J. Am. Soc. Nephrol. 12(12), 2838–47 (2001).
pubmed: 11729255
Rubin, M. F. et al. Surrogate markers of cardiovascular disease in CKD: what’s under the hood? Am. J. Kidney Dis. 57(3), 488–97 (2011).
doi: 10.1053/j.ajkd.2010.08.030
Chen, S. C. et al. Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4(1), 128–34. (2009).
doi: 10.2215/CJN.03080608
Fishbane, S. et al. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am. J. Kidney Dis. 27(5), 668–72. (1996).
doi: 10.1016/S0272-6386(96)90101-8